The retrovirus HIV-1 is the etiological agent of the decades-long AIDS pandemic. Although
vaccination is the most common preexposure route to prevent acquisition of viral disease …

The human immunodeficiency virus (HIV) replication cycle depends on the integration of its
genome within the genomic DNA of its host. Integration has represented an insurmountable …

Abstract Purpose of Review Cabotegravir is a potent integrase strand transfer inhibitor
(INSTI) recently approved as a long-acting injectable formulation for HIV prevention (CAB …

Available antiretroviral drugs have demonstrated effectiveness in both pre-exposure
prophylaxis and treatment of HIV infection. However, some concerns still persist regarding …

Modern antiretroviral therapy has demonstrated effectiveness in preexposure prophylaxis
(PrEP) and treatment of HIV infection. There is a demand for prevention and treatment …

Background Long‐acting injectable cabotegravir (CAB‐LA) represents a new additional
option for HIV prevention in people at substantial risk of HIV infection that may fill the gaps in …

The strand transfer integrase inhibitor CAB is currently being investigated as an
intramuscular preparation with a long half-life allowing for four to eight-weekly injection …

Introduction: Oral pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART)
represent the cornerstones of HIV infection prevention and treatment. However, despite their …

Introduction: Studies presented in the patent applications demonstrate that a new integrase
strand transfer inhibitor cabotegravir might be used as long-acting antiretroviral formulation …

PrEP, after approval of Truvada, continues to evolve to address adherence limitations of
daily dosing. As a long-acting injectable antiretroviral drug, cabotegravir long-acting permits …